Darusentan
From Infogalactic: the planetary knowledge core
![]() |
|
Systematic (IUPAC) name | |
---|---|
(2S)-2-(4,6-Dimethoxypyrimidin-2-yl)oxy-3-methoxy-3,3-di(phenyl)propanoic acid
|
|
Clinical data | |
Routes of administration |
Oral |
Pharmacokinetic data | |
Metabolism | Hepatic |
Biological half-life | 12.5 hours |
Identifiers | |
CAS Number | 171714-84-4 ![]() |
ATC code | none |
PubChem | CID: 177236 |
IUPHAR/BPS | 3508 |
ChemSpider | 154336 ![]() |
UNII | 33JD57L6RW ![]() |
ChEMBL | CHEMBL23261 ![]() |
Chemical data | |
Formula | C22H22N2O6 |
Molecular mass | 410.42 g/mol |
|
|
|
|
![]() ![]() |
Darusentan (LU-135252; HMR-4005) is an endothelin receptor antagonist. Gilead Colorado, a subsidiary of Gilead Sciences,[1] under license from Abbott Laboratories, is developing darusentan for the potential treatment of uncontrolled hypertension.
In June 2003, Myogen licensed the compound from Abbott for its application in the cancer field.[2]
In May 2007, a randomized, double-blind, active control, parallel assignment, safety and efficacy phase III trial was initiated in subjects who had completed the maintenance period of the DAR-312 study.
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
<templatestyles src="Asbox/styles.css"></templatestyles>
Categories:
- Pages with reference errors
- Chemical articles having calculated molecular weight overwritten
- Articles with changed InChI identifier
- Infobox drug articles without a structure image
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Endothelin receptor antagonists
- Pyrimidines
- Phenol ethers
- Pharmacology stubs